As we previously unraveled the dual role of MCs either promoting or preventing prostate cancer according to its adenocarcinoma or NE phenotype (9, 11), the identification of SV2A as a common target on MCs and NEPC prompted us to test whether levetiracetam could be effective on both prostate cancer histotypes. The gene discussed is SV2A; the disease is adenocarcinoma.